ストックスクリーナーアプリを入手
0.465
6.36%
-0.0316
前日終値:
$0.4966
開ける：
$0.5
24時間の取引高:
117.61K
Relative Volume:
0.04
時価総額：
$1.84M
収益：
$1.31M
当期純損益:
$-8.38M
株価収益率:
-0.0453
EPS:
-10.2555
ネットキャッシュフロー:
$-6.38M
1週間 パフォーマンス:
-13.28%
1か月 パフォーマンス:
-14.36%
6か月 パフォーマンス:
-46.55%
1年 パフォーマンス:
-83.57%
1日の値動き範囲:
$0.463
$0.5075
1週間の範囲:
$0.44
$0.5798
52週間の値動き範囲:
$0.44
$6.18
Scinai Immunotherapeutics Ltd Adr Stock (SCNI) Company Profile
名前
Scinai Immunotherapeutics Ltd Adr
セクター
電話
972-8-9302529
住所
JERUSALEM BIOPARK, 2ND FLOOR, JERUSALEM
Compare SCNI vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SCNI
Scinai Immunotherapeutics Ltd Adr
|
0.465 | 1.97M | 1.31M | -8.38M | -6.38M | -10.26 |
VRTX
Vertex Pharmaceuticals Inc
|
435.83 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
633.53 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.07 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.91 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.22 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Scinai Immunotherapeutics Ltd Adr (SCNI) 最新ニュース
Scinai appoints Eilon Elmalem as Yavne CDMO facility head - Investing.com
Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility - Sahm
Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe - Sahm
Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe - Benzinga
Scinai Immunotherapeutics schedules annual shareholder meeting for June 16 - Investing.com
NASDAQ gains over 100 points; Intel shares jump after strong Q1 results - MSN
Tangible book value per share of Scinai Immunotherapeutics Ltd. Sponsored ADR – FWB:2F5 - TradingView
Why Organon Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - Benzinga
Why Scinai Immunotherapeutics Stock Is Skyrocketing 90% Higher Today - Sahm
Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing - Finviz
Nasdaq Gains Over 100 Points; Intel Shares Jump After Strong Q1 Results - Benzinga
Scinai raises $2.61M in private placement to expand CDMO unit - Investing.com
Scinai raises $2.61M in private placement to expand CDMO unit By Investing.com - Investing.com South Africa
Why TopBuild Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket - Sahm
Scinai Completes Corporate Reorganization Separating CDMO and R&D Operations - Contract Pharma
Scinai completes corporate reorganization, separates CDMO unit By Investing.com - Investing.com South Africa
Cash per share of Scinai Immunotherapeutics Ltd. Sponsored ADR – FWB:2F5 - TradingView
Total debt per share of Scinai Immunotherapeutics Ltd. Sponsored ADR – FWB:2F5 - TradingView
Scinai completes corporate reorganization, separates CDMO unit - Investing.com
Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities - Barchart.com
Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration - Sahm
Scinai Immunotherapeutics (NASDAQ: SCNI) details going concern, CDMO and NanoAb risks - Stock Titan
Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring 2026 - Finviz
Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026 - Barchart.com
Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price - Finviz
Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised 12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept - Finviz
Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept - Barchart.com
SUNation Energy Inc. (NASDAQ:SUNE) Short Interest Update - Defense World
Enerflex (NYSE:EFXT) Shares Gap Up Following Dividend Announcement - Defense World
Scinai receives expanded grant for robotic manufacturing system - Investing.com
Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform - Finviz
Scinai Immunotherapeutics Buys Recipharm Israel - Contract Pharma
Scinai Immunotherapeutics (NASDAQ:SCNI) Shares Down 3.1% – Here’s Why - Defense World
Scinai Immunotherapeutics Reports Growth and Pipeline Progress - MSN
Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL - Finviz
Working capital per share of Scinai Immunotherapeutics Ltd. Sponsored ADR – MUN:2F5 - TradingView — Track All Markets
Coca-Cola HBC (OTCMKTS:CCHGY) Trading 3.7% Higher – Should You Buy? - Defense World
PCCW (OTCMKTS:PCWLF) Trading Down 7.9% – Here’s Why - Defense World
Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) Sees Large Drop in Short Interest - Defense World
Scinai Immunotherapeutics (NASDAQ:SCNI) Stock Price Down 1.3% – Should You Sell? - Defense World
Revenue per share of Scinai Immunotherapeutics Ltd. Sponsored ADR – BER:2F5 - TradingView — Track All Markets
Scinai Immunotherapeutics (NASDAQ:SCNI) Shares Up 3% – What’s Next? - Defense World
Scinai reports revenue growth as CDMO business expands By Investing.com - Investing.com India
Scinai reports revenue growth as CDMO business expands - Investing.com
Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances - Barchart.com
Revenue per share of Scinai Immunotherapeutics Ltd. Sponsored ADR – MUN:2F5 - TradingView
Scinai Immunotherapeutics schedules annual meeting for December 22 - Investing.com
Scinai receives $246,000 grant to expand biotech manufacturing - Investing.com
Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet - Finviz
Scinai’s PC111 antibody shows promise for pemphigus treatment - Investing.com
Scinai Immunotherapeutics (SCNI) FDA Approvals, PDUFA Dates & Drug Alerts 2025 - MarketBeat
Scinai Immunotherapeutics Ltd Adr (SCNI) 財務データ
収益
当期純利益
現金流量
EPS
5.06%
1.20%
大文字化:
|
ボリューム (24 時間):